- Title
- Adjuvant ovarian function suppression and cognitive function in women with breast cancer
- Creator
- Phillips, Kelly-Anne; Regan, Meredith; Abdi, Ehtesham; Domchek, Susan; Feng, Yang; Price, Karen; Coates, Alan; Gelber, Richard; Maruff, Paul; Boyle, Frances; Forbes, John F.; Ahles, Tim; Ribi, Karin; Fleming, Gini; Bernhard, Jürg; Francis, Prudence A.; Puglisi, Fabio; Bellet, Meritxell; Spazzapan, Simon; Karlsson, Per; Budman, Daniel; Zaman, Khalil
- Relation
- NHMRC.454507
- Relation
- British Journal of Cancer Vol. 114, Issue 9, p. 956-964
- Publisher Link
- http://dx.doi.org/10.1038/bjc.2016.71
- Publisher
- Nature Publishing
- Resource Type
- journal article
- Date
- 2016
- Description
- Background: To examine the effect on cognitive function of adjuvant ovarian function suppression (OFS) for breast cancer. Methods: The Suppression of Ovarian Function (SOFT) trial randomised premenopausal women with hormone receptor-positive breast cancer to 5 years adjuvant endocrine therapy with tamoxifen+OFS, exemestane+OFS or tamoxifen alone. The Co-SOFT substudy assessed objective cognitive function and patient reported outcomes at randomisation (T0), and 1 year later (T1); the primary endpoint was change in global cognitive function, measured by the composite objective cognitive function score. Data were compared for the pooled tamoxifen+OFS and exemestane+OFS groups vs the tamoxifen alone group using the Wilcoxon rank-sum test. Results: Of 86 participants, 74 underwent both T0 and T1 cognitive testing; 54 randomised to OFS+ either tamoxifen (28) or exemestane (26) and 20 randomised to tamoxifen alone. There was no significant difference in the changes in the composite cognitive function scores between the OFS+ tamoxifen or exemestane groups and the tamoxifen group (mean±s.d., −0.21±0.92 vs −0.04±0.49, respectively, P=0.71, effect size=−0.20), regardless of prior chemotherapy status, and adjusting for baseline characteristics. Conclusions: The Co-SOFT study, although limited by small samples size, provides no evidence that adding OFS to adjuvant oral endocrine therapy substantially affects global cognitive function.
- Subject
- breast cancer; ovarian function; cognitive function; quality of life; premenopausal; GnRH agonist; tamoxifen; exemestane
- Identifier
- http://hdl.handle.net/1959.13/1320772
- Identifier
- uon:24211
- Identifier
- ISSN:0007-0920
- Language
- eng
- Reviewed
- Hits: 34060
- Visitors: 24321
- Downloads: 0
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format |
|---|